Close
The Farr Institute, London is working across clinical disease areas, including:
Cancer
In the cancer workstream, the Farr Institute, London is working with the UCLPartners Cancer Programme, whose aim is to improve quality of care, patient experience and outcomes.
Cardiovascular disease
Our partners in the cardiovascular workstream include some of the UK’s leading cardiovascular research groups, with specific expertise at the interface between primary and secondary care.
Ear Nose and Throat (ENT)
Farr Institute, London and evidENT are committed to conducting high-quality research to improve health and health care for patients with ENT, Hearing and Balance problems.
Eyes
Farr investigators are working on national and international collaborative studies in each phase of translational research in paediatric ophthalmology and visual sciences.
Infection
Farr investigators in the infection workstream have a strong track record of collaboration with Public Health England (PHE), London School of Hygiene & Tropical Medicine (LSHTM) and the Sanger Institute.
Mental Health
UCL has a strong record in national primary care observational and interventional research in mental and physical health. PRIMENT Clinical Trials Unit currently coordinates 25 clinical trials.
Maternal and Child Health
Research expertise in child health, women’s health, family health/primary care, mental health and cardiovascular disease are all relevant to understanding the outcomes within families.
Musculoskeletal Disorders
The Farr Institute, London aims to establish methodology of assessing the impact of co-morbidity on surgical intervention. This will involve complex linkage methods across primary and secondary care.
Neurodegenaration
Farr investigators are working with our UCL Hospitals Biomedical Research Centre, which has a world-leading reputation to explore linkages to social care and neuroimaging data.
The research spans across primary and secondary care to deliver impact across the whole translational cycle from biological discovery including omics and digital phenotyping with imaging through innovative trials to improving clinical practice, service delivery, patient outcomes and public health.